

**Table SI. Search strategy for the systematic review, according to bibliographic database**

**Pubmed**

<p>1. "Hidradenitis Suppurativa"[Mesh]                  2. "Hidradenitis"[Mesh]                  3. <b>1 OR 2</b></p>
<p style="text-align: center;"><b>Adverse effects in fetus, neonate or during pregnancy</b></p> <p>4. Pregnancy [Mesh]                  5. Pregnancy Outcome [Mesh]                  6. Pregnancy Complications [Mesh]                  7. Abortion, Induced [Mesh]                  8. Obstetric Surgical Procedures [Mesh]                  9. Delivery, Obstetric [Mesh]                  10. Preconception Care [Mesh]                  11. Maternal Health Services [Mesh]                  12. Infant, Newborn [Mesh]                  13. Infant, Low Birth Weight [Mesh]                  14. Premature Birth [Mesh]                  15. Congenital Abnormalities [Mesh]                  16. Perinatal Mortality [Mesh]                  17. Infant Mortality [Mesh]                  18. Perinatal Death [Mesh]                  19. Intensive Care, Neonatal [Mesh]                  20. Neonatal Sepsis [Mesh]                  21. Infant, Newborn, Diseases [Mesh]                  22. Infant, Premature [Mesh]                  23. Fetal Diseases [Mesh]                  24. <b>4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23</b></p>
<p style="text-align: center;"><b>Biologic therapy for treating hidradenitis suppurativa</b></p> <p>25. Antibodies, Monoclonal, Humanized [Mesh]                  26. Antibodies, Anti-Idiotypic [Mesh]                  27. Infliximab [Mesh]                  28. Etanercept [Mesh]                  29. Adalimumab [Mesh]                  30. Certolizumab Pegol [Mesh]                  31. Ustekinumab [Mesh]                  32. Secukinumab [Supplementary Concept]                  33. Brodalumab [Supplementary Concept]                  34. Bimekizumab [Supplementary Concept]                  35. Ixekizumab [Supplementary Concept]                  36. Risankizumab [Supplementary Concept]                  37. Guselkumab [Supplementary Concept]                  38. Tildrakizumab [Supplementary Concept]                  39. Interleukin 1 Receptor Antagonist Protein [Mesh]                  40. Bermekimab [Supplementary Concept]                  41. Apremilast [Supplementary Concept]                  42. Upadacitinib [Supplementary Concept]                  43. Janus Kinase Inhibitors [Mesh]                  44. Spesolimab [Supplementary Concept]                  45. Biological Therapy [Mesh]                  46. Biological Products [Mesh]                  47. Antibodies, Monoclonal [Mesh]                  48. Tumor Necrosis Factor-alpha [Mesh]                  49. Interleukins [Mesh]                  50. Receptors, Interleukin [Mesh]                  51. <b>25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33 OR 34 OR 35 OR 36 OR 37 OR 38 OR 39 OR 40 OR 41 OR 42 OR 43 OR 44 OR 45 OR 46 OR 47 OR 48 OR 49 OR 50</b></p>
<p style="text-align: center;"><b>Final search string: 3 AND 24 AND 50 (no filters)</b>  <b>Search results: 9 records</b></p>

## Scopus

1. Hidradenitis suppurativa 2. Hidradenitis 3. Acne inversa 4. <b>1 OR 2 OR 3 (in title, abstract, and key words)</b>
<b>Adverse effects in fetus, neonate or during pregnancy</b>
5. Pregnancy 6. Gestational 7. Pregnant 8. <b>5 OR 6 OR 7</b>
<b>Biologic therapy for treating hidradenitis suppurativa</b>
9. Biologic 10. Monoclonal antibody 11. Infliximab 12. Etanercept 13. Adalimumab 14. Certolizumab pegol 15. Ustekinumab 16. Secukinumab 17. Brodalumab 18. Bimekizumab 19. Ixekizumab 20. Risankizumab 21. Guselkumab 22. Tildrakizumab 23. Apremilast 24. Upadacitinib 25. Spesolimab 26. <b>9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 (in title, abstract, and key words)</b>
<b>Final search string: 4 AND 8 AND 19 (no filters)</b> <b>Search results: 167 records</b>

## Web of Science

1. ALL=(hidradenitis suppurativa) 2. ALL=(hidradenitis) 3. ALL=(acne inversa) 4. <b>1 OR 2 OR 3</b>
<b>Adverse effects in fetus, neonate or during pregnancy</b>
5. ALL=(pregnancy) 6. ALL=(gestational) 7. ALL=(pregnant) 8. ALL=(spontaneous abortion) 9. ALL=(miscarriage) 10. ALL=(induced abortion) 11. ALL=(congenital disorder) 12. ALL=(prematurity) 13. ALL=(newborn) 14. ALL=(infant) 15. <b>5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14</b>
<b>Biologic therapy for treating hidradenitis suppurativa</b>
16. ALL=(biologic) 17. ALL=(biological) 18. ALL=(infliximab) 19. ALL=(etanercept) 20. ALL=(adalimumab) 21. ALL=(certolizumab pegol) 22. ALL=(ustekinumab) 23. ALL=(secukinumab) 24. ALL=(brodalumab) 25. ALL=(bimekizumab)

26. ALL=(ixekizumab)
27. ALL=(risankizumab)
28. ALL=(guselkumab)
29. ALL=(tildrakizumab)
30. ALL=(apremilast)
31. ALL=(upadacitinib)
32. ALL=(spesolimab)
33. ALL=(monoclonal antibody)
34. **16 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 OR 31 OR 32 OR 33**

**Final search string: 4 AND 15 AND 34 (no filters)  
Search results: 26 records**

## Embase

1. 'Hidradenitis' AND 'suppurativa'/exp
2. 'Hidradenitis':ab,ti
3. 'Hidradenitis' AND 'suppurativa':ab,ti
4. 'acne' AND 'inversa':ab,ti
5. **1 OR 2 OR 3 OR 4**

### **Adverse effects in fetus, neonate or during pregnancy**

6. 'pregnancy':ab,ti
7. 'pregnancy'/exp
8. 'gestational':ab,ti
9. 'pregnant':ab,ti
10. **6 OR 7 OR 8 OR 9**

### **Biologic therapy for treating hidradenitis suppurativa**

11. 'biologic':ab,ti
12. 'biological':ab,ti
13. 'biologic'/exp
14. 'monoclonal antibody'/exp
15. 'infliximab':ab,ti
16. 'etanercept':ab,ti
17. 'adalimumab':ab,ti
18. 'certolizumab':ab,ti
19. 'ustekinumab':ab,ti
20. 'secukinumab':ab,ti
21. 'brodalumab':ab,ti
22. 'bimekizumab':ab,ti
23. 'ixekizumab':ab,ti
24. 'risankizumab':ab,ti
25. 'guselkumab':ab,ti
26. 'tildrakizumab':ab,ti
27. 'apremilast':ab,ti
28. 'upadacitinib':ab,ti
29. 'spesolimab':ab,ti
30. **11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29**

**Final search string: 6 AND 11 AND 24 (no filters)  
Search results: 49 records**

**Table SII. Methodological quality assessment of included studies: Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I)<sup>1</sup>**

**1. Boggs 2020<sup>2</sup>**

**Type of study:** Case series

**Participants:** Pregnant women with severe hidradenitis suppurativa

**Experimental intervention:** Infliximab, adalimumab, ustekinumab

**Control intervention:** none

Outcome	Benefit or harm of intervention	Domains							Overall Risk of Bias
		<i>Bias due to confounding</i>	<i>Bias in selection of participants into the study</i>	<i>Bias in classification of interventions</i>	<i>Bias due to deviations from intended interventions</i>	<i>Bias due to missing data</i>	<i>Bias in measurement of outcomes</i>	<i>Bias in selection of the reported result</i>	
Live births	Harm	Critical <sup>1</sup>	Low <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	Low <sup>6</sup>	Serious <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Spontaneous abortions (SA)	Harm	Critical <sup>1</sup>	Low <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	Low <sup>6</sup>	Serious <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Elective abortions (EA)	Harm	Critical <sup>1</sup>	Low <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	Low <sup>6</sup>	Serious <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Congenital malformation (CM)	Harm	Critical <sup>1</sup>	Low <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	Low <sup>6</sup>	Serious <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Preterm birth (PTB)	Harm	Critical <sup>1</sup>	Low <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	Low <sup>6</sup>	Serious <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Small for gestational age (SGA)	Harm	Critical <sup>1</sup>	Low <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	Low <sup>6</sup>	Serious <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Low birth weight (LBW)	Harm	Critical <sup>1</sup>	Low <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	Low <sup>6</sup>	Serious <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Neonatal outcomes	Harm	Critical <sup>1</sup>	Low <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	Low <sup>6</sup>	Serious <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Long-term growth and development	Harm	Critical <sup>1</sup>	Low <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	Low <sup>6</sup>	Serious <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>

**Explanatory Footnotes**

1. Bias due to confounding as confounding inherently was not controllable.
2. Bias due to selection of participants into the study as selection into the study was very strongly related to intervention and outcome; and this could not be adjusted for in analyses.
3. Bias due to classification of interventions as major aspects of the assignments of intervention status were determined in a way that could have been affected by knowledge of the outcome.
4. Bias due to deviations from intended interventions as any deviations from intended intervention reflected usual practice.
5. Bias due to missing data as data were reasonably complete.
6. No information is reported about the methods of outcome assessment.
7. There is too little information to make a judgement.
8. Overall Risk of Bias: the study is judged to be at critical risk of bias in at least one domain.

## 2. Gisondi 2025<sup>3</sup>

**Type of study:** Case report

**Participants:** Pregnant woman with severe hidradenitis suppurativa

**Experimental intervention:** Certolizumab pegol and adalimumab

**Control intervention:** none

Outcome	Benefit or harm of intervention	Domains							Overall Risk of Bias
		<i>Bias due to confounding</i>	<i>Bias in selection of participants into the study</i>	<i>Bias in classification of interventions</i>	<i>Bias due to deviations from intended interventions</i>	<i>Bias due to missing data</i>	<i>Bias in measurement of outcomes</i>	<i>Bias in selection of the reported result</i>	
Live births	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Spontaneous abortions (SA)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Elective abortions (EA)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Congenital malformation (CM)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Preterm birth (PTB)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Small for gestational age (SGA)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Low birth weight (LBW)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Neonatal outcomes	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Long-term growth and development	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>

### Explanatory Footnotes

1. Bias due to confounding as confounding inherently was not controllable.
2. Bias due to selection of participants into the study as selection into the study was very strongly related to intervention and outcome; and this could not be adjusted for in analyses.
3. Bias due to classification of interventions as major aspects of the assignments of intervention status were determined in a way that could have been affected by knowledge of the outcome.
4. Bias due to deviations from intended interventions as any deviations from intended intervention reflected usual practice.
5. Bias due to missing data as data were reasonably complete.
6. No information is reported about the methods of outcome assessment.
7. There is too little information to make a judgement.
8. Overall Risk of Bias: the study is judged to be at critical risk of bias in at least one domain.

### 3. Kok 2021<sup>4</sup>

**Type of study:** Case report

**Participants:** Pregnant woman with severe hidradenitis suppurativa

**Experimental intervention:** Tildrakizumab

**Control intervention:** none

Outcome	Benefit or harm of intervention	Domains							Overall Risk of Bias
		<i>Bias due to confounding</i>	<i>Bias in selection of participants into the study</i>	<i>Bias in classification of interventions</i>	<i>Bias due to deviations from intended interventions</i>	<i>Bias due to missing data</i>	<i>Bias in measurement of outcomes</i>	<i>Bias in selection of the reported result</i>	
Live births	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Spontaneous abortions (SA)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Elective abortions (EA)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Congenital malformation (CM)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Preterm birth (PTB)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Small for gestational age (SGA)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Low birth weight (LBW)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Neonatal outcomes	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Long-term growth and development	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>

#### Explanatory Footnotes

1. Bias due to confounding as confounding inherently was not controllable.
2. Bias due to selection of participants into the study as selection into the study was very strongly related to intervention and outcome; and this could not be adjusted for in analyses.
3. Bias due to classification of interventions as major aspects of the assignments of intervention status were determined in a way that could have been affected by knowledge of the outcome.
4. Bias due to deviations from intended interventions as any deviations from intended intervention reflected usual practice.
5. Bias due to missing data as data were reasonably complete.
6. No information is reported about the methods of outcome assessment.
7. There is too little information to make a judgement.
8. Overall Risk of Bias: the study is judged to be at critical risk of bias in at least one domain.

#### 4. Melgosa Ramos 2022<sup>5</sup>

**Type of study:** Case report

**Participants:** Pregnant woman with hidradenitis suppurativa

**Experimental intervention:** Certolizumab pegol and adalimumab

**Control intervention:** none

Outcome	Benefit or harm of intervention	Domains							Overall Risk of Bias
		<i>Bias due to confounding</i>	<i>Bias in selection of participants into the study</i>	<i>Bias in classification of interventions</i>	<i>Bias due to deviations from intended interventions</i>	<i>Bias due to missing data</i>	<i>Bias in measurement of outcomes</i>	<i>Bias in selection of the reported result</i>	
Live births	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Spontaneous abortions (SA)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Elective abortions (EA)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Congenital malformation (CM)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Preterm birth (PTB)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Small for gestational age (SGA)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Low birth weight (LBW)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Neonatal outcomes	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Long-term growth and development	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>

#### Explanatory Footnotes

1. Bias due to confounding as confounding inherently was not controllable.
2. Bias due to selection of participants into the study as selection into the study was very strongly related to intervention and outcome; and this could not be adjusted for in analyses.
3. Bias due to classification of interventions as major aspects of the assignments of intervention status were determined in a way that could have been affected by knowledge of the outcome.
4. Bias due to deviations from intended interventions as any deviations from intended intervention reflected usual practice.
5. Bias due to missing data as data were reasonably complete.
6. No information is reported about the methods of outcome assessment.
7. There is too little information to make a judgement.
8. Overall Risk of Bias: the study is judged to be at critical risk of bias in at least one domain.

## 5. Repetto 2021<sup>6</sup>

**Type of study:** Case series

**Participants:** Pregnant woman with severe hidradenitis suppurativa

**Experimental intervention:** Certolizumab pegol

**Control intervention:** none

Outcome	Benefit or harm of intervention	Domains							Overall Risk of Bias
		<i>Bias due to confounding</i>	<i>Bias in selection of participants into the study</i>	<i>Bias in classification of interventions</i>	<i>Bias due to deviations from intended interventions</i>	<i>Bias due to missing data</i>	<i>Bias in measurement of outcomes</i>	<i>Bias in selection of the reported result</i>	
Live births	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Spontaneous abortions (SA)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Elective abortions (EA)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Congenital malformation (CM)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Preterm birth (PTB)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Small for gestational age (SGA)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Low birth weight (LBW)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Neonatal outcomes	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Long-term growth and development	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>

### Explanatory Footnotes

1. Bias due to confounding as confounding inherently was not controllable.
2. Bias due to selection of participants into the study as selection into the study was very strongly related to intervention and outcome; and this could not be adjusted for in analyses.
3. Bias due to classification of interventions as major aspects of the assignments of intervention status were determined in a way that could have been affected by knowledge of the outcome.
4. Bias due to deviations from intended interventions as any deviations from intended intervention reflected usual practice.
5. Bias due to missing data as data were reasonably complete.
6. No information is reported about the methods of outcome assessment.
7. There is too little information to make a judgement.
8. Overall Risk of Bias: the study is judged to be at critical risk of bias in at least one domain.

## 6. Samuel 2018<sup>7</sup>

**Type of study:** Case report

**Participants:** Pregnant woman with severe hidradenitis suppurativa

**Experimental intervention:** Adalimumab

**Control intervention:** none

Outcome	Benefit or harm of intervention	Domains							Overall Risk of Bias
		<i>Bias due to confounding</i>	<i>Bias in selection of participants into the study</i>	<i>Bias in classification of interventions</i>	<i>Bias due to deviations from intended interventions</i>	<i>Bias due to missing data</i>	<i>Bias in measurement of outcomes</i>	<i>Bias in selection of the reported result</i>	
Live births	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Spontaneous abortions (SA)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Elective abortions (EA)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Congenital malformation (CM)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Preterm birth (PTB)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Small for gestational age (SGA)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Low birth weight (LBW)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Neonatal outcomes	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Long-term growth and development	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>

### Explanatory Footnotes

1. Bias due to confounding as confounding inherently was not controllable.
2. Bias due to selection of participants into the study as selection into the study was very strongly related to intervention and outcome; and this could not be adjusted for in analyses.
3. Bias due to classification of interventions as major aspects of the assignments of intervention status were determined in a way that could have been affected by knowledge of the outcome.
4. Bias due to deviations from intended interventions as any deviations from intended intervention reflected usual practice.
5. Bias due to missing data as data were reasonably complete.
6. No information is reported about the methods of outcome assessment.
7. There is too little information to make a judgement.
8. Overall Risk of Bias: the study is judged to be at critical risk of bias in at least one domain.

## 7. Wohlmuth-Wieser 2021<sup>8</sup>

**Type of study:** Case report

**Participants:** Pregnant woman with severe hidradenitis suppurativa

**Experimental intervention:** Certolizumab pegol and adalimumab

**Control intervention:** none

Outcome	Benefit or harm of intervention	Domains							Overall Risk of Bias
		<i>Bias due to confounding</i>	<i>Bias in selection of participants into the study</i>	<i>Bias in classification of interventions</i>	<i>Bias due to deviations from intended interventions</i>	<i>Bias due to missing data</i>	<i>Bias in measurement of outcomes</i>	<i>Bias in selection of the reported result</i>	
Live births	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Spontaneous abortions (SA)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Elective abortions (EA)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Congenital malformation (CM)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Preterm birth (PTB)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Small for gestational age (SGA)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Low birth weight (LBW)	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Neonatal outcomes	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>
Long-term growth and development	Harm	Critical <sup>1</sup>	Critical <sup>2</sup>	Serious <sup>3</sup>	Low <sup>4</sup>	Low <sup>5</sup>	No information <sup>6</sup>	No information <sup>7</sup>	<b>CRITICAL<sup>8</sup></b>

### Explanatory Footnotes

1. Bias due to confounding as confounding inherently was not controllable.
2. Bias due to selection of participants into the study as selection into the study was very strongly related to intervention and outcome; and this could not be adjusted for in analyses.
3. Bias due to classification of interventions as major aspects of the assignments of intervention status were determined in a way that could have been affected by knowledge of the outcome.
4. Bias due to deviations from intended interventions as any deviations from intended intervention reflected usual practice.
5. Bias due to missing data as data were reasonably complete.
6. No information is reported about the methods of outcome assessment.
7. There is too little information to make a judgement.
8. Overall Risk of Bias: the study is judged to be at critical risk of bias in at least one domain.